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Repeated Mechanical Endovascular 
Thrombectomy for Recurrent Large Vessel 
Occlusion
A Multicenter Experience
Ghada A. Mohamed , MD; Hassan  Aboul Nour , MD; Raul G. Nogueira , MD; Mahmoud H. Mohammaden, MD;  
Diogo C. Haussen , MD; Alhamza R. Al-Bayati , MD; Thanh N. Nguyen , MD; Mohamad Abdalkader , MD;  
Artem Kaliaev, MD; Alice  Ma , MD; Johanna Fifi , MD; Jacob Morey , MD; Dileep R. Yavagal , MD; Vasu Saini , MD;  
Santiago Ortega-Gutierrez , MD; Mudassir Farooqui , MD; Cynthia B. Zevallos , MD; Darko Quispe-Orozco , MD;  
Lonni Schultz, PhD; Maximilian Kole, MD; Daniel Miller, MD; Stephan A. Mayer , MD; Horia Marin , MD; Alex Bou Chebl , MD
BACKGROUND AND PURPOSE: Mechanical thrombectomy (MT) is now the standard of care for large vessel occlusion (LVO) 
stroke. However, little is known about the frequency and outcomes of repeat MT (rMT) for patients with recurrent LVO.
METHODS: This is a retrospective multicenter cohort of patients who underwent rMT at 6 tertiary institutions in the United 
States between March 2016 and March 2020. Procedural, imaging, and outcome data were evaluated. Outcome at discharge 
was evaluated using the modified Rankin Scale.
RESULTS: Of 3059 patients treated with MT during the study period, 56 (1.8%) underwent at least 1 rMT. Fifty-four (96%) 
patients were analyzed; median age was 64 years. The median time interval between index MT and rMT was 2 days; 35 of 
54 patients (65%) experienced recurrent LVO during the index hospitalization. The mechanism of stroke was cardioembolism 
in 30 patients (56%), intracranial atherosclerosis in 4 patients (7%), extracranial atherosclerosis in 2 patients (4%), and 
other causes in 18 patients (33%). A final TICI recanalization score of 2b or 3 was achieved in all 54 patients during index 
MT (100%) and in 51 of 54 patients (94%) during rMT. Thirty-two of 54 patients (59%) experienced recurrent LVO of a 
previously treated artery, mostly the pretreated left MCA (23 patients, 73%). Fifty of the 54 patients (93%) had a documented 
discharge modified Rankin Scale after rMT: 15 (30%) had minimal or no disability (modified Rankin Scale score ≤2), 25 
(50%) had moderate to severe disability (modified Rankin Scale score 3–5), and 10 (20%) died.
CONCLUSIONS: Almost 2% of patients treated with MT experience recurrent LVO, usually of a previously treated artery during 
the same hospitalization. Repeat MT seems to be safe and effective for attaining vessel recanalization, and good outcome 
can be expected in 30% of patients.
Key Words: arteries ◼ atherosclerosis ◼ ischemic stroke ◼ standard of care ◼ thrombectomy
In 2015, mechanical thrombectomy (MT) became the standard of care for the treatment of acute ischemic stroke due to large vessel occlusion (LVO) within 6 
hours.1,2 In 2018, the treatment window was expanded 
up to 24 hours from acute ischemic stroke symptom 
onset.3,4 On average, the 5-year risk of acute ischemic 
stroke recurrence is 24% for women and 42% for men, 
with most of the risk within the first 2 weeks after the 
index event.5,6 With estimates of 65 000 to 90 000 
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States, the number of patients who may experience a 
recurrent LVO (rLVO) requiring repeat MT (rMT) may 
be substantial.7
The literature on the safety and outcomes of rMT, 
especially in the same vascular territory, is limited. 
Fandler et al8 showed that successful rMT could be 
achieved in a patient with recurrent early reocclusion 
of the same artery within 24 hours. Bouslama et al9 
reported on 14 patients with rMT and showed that there 
were no statistically significant differences in demo-
graphics, stroke severity, time from last known nor-
mal to groin puncture, reperfusion rates, hemorrhagic 
complications, good functional outcomes, or mortality 
between patients who underwent rMT and those who 
were treated with a single thrombectomy.
The cause of rLVO is also not well described. Up to 
20% of LVO is caused by atherosclerosis because of 
plaque rupture leading to vessel thrombosis or artery-
to-artery embolism.10 A population-based study showed 
that atherosclerotic large vessel disease carried the high-
est risk of stroke recurrence.11 This risk correlates with 
plaque echogenicity.12Additionally, atrial fibrillation, which 
is the primary cause of cardioembolic stroke, is associ-
ated with increased risk for early stroke recurrence.12
Understanding the frequency, timing, causes, and 
angiographic and clinical outcomes associated with rMT 
may help develop preventive medical strategies and opti-
mize the endovascular approach (ie, use of stent-retriever 
versus suction thrombectomy versus angioplasty/stent-
ing). In this study, we aimed to describe our cumulative 
experience with consecutive cases of rMT for rLVO at 6 
US medical centers over a period of 4 years.
METHODS
Study Design
Repeated Mechanical Endovascular Thrombectomy for 
Recurrent Large Vessel Occlusion is a retrospective multicenter 
cohort study that identified patients who underwent rMT at 6 
United States comprehensive stroke centers between March 
2016 and March 2020. All data were prospectively collected 
in endovascular databases maintained by the investigators. The 
institutional review boards of all 6 institutions approved this 
study, which included a data-sharing agreement. The data that 
support the findings of this study are available from the cor-
responding author upon reasonable request.
Clinical Variables
Patients who received an index MT (iMT) in the 6 partici-
pating centers were analyzed, and cases in which rMT was 
performed were identified. All patients received baseline 
noncontrast computed tomography (NCCT), CT angiogra-
phy upon presentation, and 24 hours postprocedural NCCT 
or earlier if clinically indicated. Stroke work-up included 
in-hospital cardiac rhythm monitoring, and transthoracic or 
transesophageal echocardiography in all cases. Antiplatelet 
agents were started either immediately or within 24 hours 
after thrombectomy unless hemorrhagic infarction was pres-
ent. Anticoagulation when indicated for atrial fibrillation was 
started between 3 and 14 days after thrombectomy unless 
hemorrhage was present.
Demographics, risk factors, clinical, imaging, procedural 
devices used, number of passes, final TICI score, post-iMT 
antithrombotic therapy, and outcome at discharge were 
collected. We defined early reocclusion as occurring dur-
ing the index hospitalization. Stroke severity was mea-
sured with the National Institutes of Health Stroke Scale 
(NIHSS).13 Stroke cause was classified based on the TOAST 
criteria.14 Successful reperfusion was defined as a modi-
fied Thrombolysis in Cerebral Infarction score of 2b or 3.15 
Postprocedural hemorrhagic complications were defined 
using the European Cooperative Acute Stroke Study crite-
ria.16 Neurological outcomes were measured with the modi-
fied Rankin Scale (mRS) at the time of hospital discharge. 
Favorable outcome was defined as mRS score <2 and unfa-
vorable as mRS score 3 to 5, with mortality mRS score 6 
counted separately.
Treatment plans were based on each hospital’s protocol, 
including various interventional approaches, for example, aspi-
ration catheters, stent retriever devices, stents, angioplasty bal-
loons, or combinations thereof.
Statistical Analysis
We used proportions, median, and interquartile ranges for 
descriptive statistics. For comparisons between iMT and rMT, 
McNemar tests were used for the dichotomized variables, 
Bowker test for symmetry for the categorical variables, and 
Wilcoxon signed-rank tests for the continuous variables. 
For comparisons between patients with reocclusion dur-
ing hospitalization and reocclusion after discharge, Fisher 
exact test was used for dichotomized and categorical vari-
ables and Wilcoxon 2-sample tests for continuous variables. 
Significance was set at <0.05, and 2-sided P values were 
reported. Statistical analysis was performed using R Software 
(version 3.6.1) and SAS (version 9.4).
RESULTS
Of 3059 patients who underwent MT at 6 comprehensive 
stroke centers between March 2018 and March 2020, 
56 patients (1.8%) underwent rMT. Fifty-four patients 
Nonstandard Abbreviations and Acronyms
iMT index mechanical thrombectomy
LVO large vessel occlusion
mRS modified Rankin Scale
MT mechanical thrombectomy
NIHSS  National Institutes of Health Stroke 
Scale
rLVO recurrent LVO
rMT repeat mechanical thrombectomy
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were analyzed, with 2 patients excluded because of 
incomplete iMT clinical and procedural data.
Fifty patients (93%) had 1 rMT, 3 (6%) underwent 2 
rMT procedures, and 1 (2%) had rMT performed 3 times. 
Median age was 64 (interquartile range, 54–72) years, 
and 50% were females (Table 1).
Median time interval between the index LVO (iLVO) 
and rLVO was 2 days (range, 0.8–17.8 days); in 35 
patients (65%), rMT was performed during the index 
hospitalization (Table 2). There was no statistically sig-
nificant difference in stroke cause, ASPECTS (Alberta 
Stroke Program Early CT Score), number of passes dur-
ing MT, or final modified Thrombolysis in Cerebral Infarc-
tion score between those who had reocclusion during 
hospitalization or reocclusion after discharge (Table 3).
At the time of rMT, 13 patients (24%) were not 
started on any antithrombotic therapy, 27 patients (50%) 
received antiplatelet therapy, and 14 patients (26%) 
were on full anticoagulation (Table 1). Patients with rLVO 
during hospitalization were less commonly receiving sec-
ondary stroke prevention compared with patients with 
rLVO after discharge (34% versus 5%, P=0.022). Both 
groups had similar discharge mRS (Table 3).
In 30 patients (56%), rLVO occurred in patients with a 
cardioembolic cause of stroke, with the majority of these 
(23 of 35, 77%) due to atrial fibrillation. Six patients 
(11%) had rLVO due to atherosclerotic in situ thrombo-
sis: intracranial atherosclerotic disease in 4 (7%), and 
extracranial atherosclerosis in 2 (4%). In the remaining 
18 patients (33%) rLVO was secondary to other causes 
(eg, vasculitis) or was cryptogenic (Table 2).
Thirty-two of 54 patients (59%) had rLVO of the same 
vessel treated during iMT. The most common stroke 
cause in these patients was cardiac embolism (13/32, 
41%), and the left MCA was the most commonly affected 
vessel in these cases (23/32, 72%) (Table 2). Of the 4 
patients who underwent 2 or more rMT procedures, 3 
had atrial fibrillation and 1 patient had intracranial stent 
thrombosis. The single patient who underwent 3 repeat 
thrombectomies had atrial fibrillation and developed a 
fixed focal stenosis of the repeatedly treated left MCA 
that eventually required angioplasty.
Median NIHSS at presentation was 14 (range, 9–21) 
for iLVO and 16 (range, 10–24) for rLVO (P=0.96, 
Table 2). However, post MT NIHSS scores were worse 
after rMT compared with iMT (median 12 versus 7, 
P=0.008, Table 2) and worse when rMT was performed 
during the same hospitalization compared with those 
with reocclusion after discharge (median 7 versus 5, 
P=0.028, Table 3).
Successful revascularization was achieved with 1 
pass in 32 of 54 patients (59%) during iMT and in 26 
(48%) during rMT. A final recanalization score of modi-
fied Thrombolysis in Cerebral Infarction 2b or 3 was 
achieved in all 54 patients during their iMT (100%) and 
in 51 of 54 patients (94%) during rMT (Table 2).
Postprocedural intracerebral hemorrhage occurred in 
4 of 54 patients (7%) after iMT, 2 of which were symp-
tomatic. After rMT, 7 of 54 patients (13%) had postpro-
cedure intracerebral hemorrhage, 4 of which (7%) were 
symptomatic, of 2 of which were fatal (Table 2).
Fifty of 54 patients (93%) had a documented dis-
charge mRS after rMT: 15 (30%) had minimal or no 
disability (mRS score ≤2), 25 (50%) had moderate to 
severe disability (mRS score 3–5), and 10 (20%) died 
(Table 2).
DISCUSSION
Large vessel occlusion (LVO) accounts for 30% of isch-
emic stroke presentations.17 The 5-year risk of ischemic 
stroke recurrence due to all stroke etiologies combined 
is about 30%.18 To our knowledge, our study represents 
the largest cohort of patients receiving rMT for rLVO 
in North America to date. In this cohort, rLVO requiring 
MT was infrequent, occurring after 1.8% of all MT pro-
cedures. Similar and slightly lower rates (0.4%–1.5%) 
have been previously reported in smaller series.9,19–22 
These infrequent treatment rates likely represent an 
underestimate of the actual number of rLVO due to: 
exclusion of patients with rLVO with severe disability, 
patients presenting with rLVO to different hospitals, and 
missed rLVO during hospitalization in patients with a 
subtle worsening of the original NIHSS.
In our cohort, the majority of rLVO occurred early, 
within a median time to reocclusion of 2 days. Thirty-five 
patients, 65% developed rLVO during the index hos-
pitalization after successful iMT. A study on very early 
reocclusion within 48 hours showed that cardio-embo-
lism and atherosclerotic large vessel disease were the 
first and second most common etiologies associated 
with reocclusion after successful revascularization.23 
We found similar results, with cardioembolism (51%) 
and large vessel atherosclerosis (17%) being the most 
likely stroke mechanisms associated with early rLVO. 
Other causes that may contribute to early reocclusion 
Table 1. Demographics of 54 Patients Treated With Repeat 
Mechanical Thrombectomy
Characteristic N=54
Age, y 64 (54–72)
Female 27 (50)
LVO recurrence after the index event
  One recurrence 50 (93)
 Two recurrences 3 (6)
 Three recurrences 1 (12)
Time interval in days between index MT and first rMT, d 2 (0.8–17.8)
Reocclusion during index hospitalization 35 (65)
Reocclusion of same vascular territory 32 (59)
Data are N (%) or median (IQR). LVO indicates large vessel occlusion; MT, 
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are procedure-related complications like dissection and 
stent thrombosis.22 These complications were infre-
quent in our cohort.
The primary cause for rLVO in our cohort was car-
dioembolic source, about 56% of the 54 patients, with 
majority due to atrial fibrillation (77%). This is consistent 
with prior studies showing that cardioembolic source is 
the cause of up to 40% of acute ischemic strokes,24 and 
43% to 67% of rLVO.19–22
Thirty-two of the 54 patients in our cohort (59%) 
had reocclusion of the previously treated artery. Recur-
rent LVO of the same vessel might intuitively seem more 
likely to occur in patients with intracranial atherosclerotic 
disease or extracranial atherosclerosis. On the contrary, 
Table 2. Procedural Characteristics Comparing Index Mechani-
cal Thrombectomy and the First Recurrent Thrombectomy
Characteristic Index MT First rMT P value
Presenting NIHSS 14 (9–21) 16 (10–24) 0.16*
ASPECTS 9 (8–10) 9 (8–10) 0.96*
Postprocedural NIHSS 7 (3–12) 12 (5–21) 0.008*
Arterial territory 0.45†
 MCA 40 (74) 34 (63)
 Basilar artery 6 (11) 9 (17)
 ICA 7 (13) 10 (17)
 PCA 1 (2) 1 (2)
Endovascular approach 0.018†
 Stent retriever 43 41
 Aspiration 13 20
 Intracranial angioplasty 1 3
 Intracranial stenting 0 3
 Extracranial angioplasty 0 0
 Extracranial stenting 0 2
Number of passes 0.32‡
 1 pass 32 (59) 26 (48)
 >1 pass 22 (41) 28 (52)
mTICI score 0.25‡
 2b-3 54 (100) 51 (94)
 1–2a 0 (0) 3 (6)
Hemorrhage 4 (7) 7 (13) 0.18‡
 Symptomatic§ 2 (4) 4 (7)
 Fatal 0 (0) 2 (4)
Stroke cause 0.75†
 Cardioembolic 30 (56) 30 (56)  
  Intracranial atherosclerotic 
disease
4 (7) 4 (7)  
  Extracranial atherosclerotic 
disease
4 (7) 4 (7)  
 Other causes 16 (30) 18 (33)  
  Cryptogenic 11 (20) 11 (20)  
  Vasculitis 1 (2) 1 (2)  
  Dissection 0 (0) 1 (2)  
  Hypercoagulable state 4 (7) 4 (7)  
  Stent thrombosis 0 (0) 1 (2)  
Follow-up mRS N=45 N=50  
 Favorable (mRS score ≤2) 17 (38) 15 (30)
 Unfavorable (mRS score 3–5) 28 (62) 25 (50)
 Death (mRS score 6)  10 (20)
Data are N (%) or median (IQR). ACA indicates anterior cerebral artery; 
ASPECTS, Alberta Stroke Program Early CT Score; ESUS, embolic stroke of 
undetermined source; ICA, internal carotid artery; ICH, intracerebral hemorrhage; 
IQR, interquartile range; MCA, middle cerebral artery; mRS, modified Rankin Scale; 
MT, mechanical thrombectomy; mTICI, modified Thrombolysis in Cerebral Infarc-
tion; NIHSS, National Institutes of Health Stroke Scale; PCA, posterior cerebral 
artery; and RT, recurrent thrombectomy.
*P value from signed-rank test.
†P value from Bowker test for symmetry.
‡P value from McNemar test.
§Symptomatic hemorrhage corresponds to PH2 (hematoma occupying 30% or 
more of the infarcted tissue, with obvious mass effect) according to the Heidel-
berg bleeding classification.
Table 3. Comparison Between Reocclusion During Index 










Age, y 62 (53–68) 67 (60.5–80) 0.07*
ASPECTS 9 (8–10) 9 (7.5–9) 0.19*
Postprocedural NIHSS 7 (4–14) 5 (1–7) 0.028*
Time interval, d 1 (0–2) 75 (11–390) <0.001*
Number of passes  14 (74) 0.15†
 1 pass 18 (51) 5 (26)
 >1 pass 17 (49)  
Index stroke cause  12 (63) 0.78
 Cardioembolic 18 (51) 2 (11)
 Atherosclerotic 6 (17) 5 (26)
 Other causes 11 (31)  
Reocclusion of same vascular 
territory
24 (69) 8 (42) 0.08†
Need for stenting, angio-
plasty, or both
0 (0) 0.043†
 Yes 7 (20) 19 (100)
 No 28 (80)
Medications used following 
index MER
 1 (5) 0.02†
10 (53)
 None 12 (34) 8 (42)  
 Antiplatelets 17 (49)
 Anticoagulation 6 (17)
Follow-up mRS N=32 N=18 0.28*
 Favorable mRS (≤2) 10 (31) 5 (28)
7 (39)
 Unfavorable mRS (3–5) 18 (56) 6 (33)
 Death 4 (13)
Follow-up mRS, median (IQR) N=32 N=18 0.39*
4 (2–4.5) 4 (1–6)
Data are N (%) or median (IQR). ASPECTS indicates Alberta Stroke Pro-
gram Early CT Score; IQR, interquartile range; mRS, modified Rankin Scale; and 
NIHSS, National Institutes of Health Stroke Scale.
*P value from Wilcoxon 22-sample test.
†P value from Fisher exact test. 
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in our series, cardioembolism was the most common 
stroke mechanism associated with reocclusion of the 
pretreated artery (41% of the 32 patients), and the left 
MCA was more commonly affected than the right. This 
finding may be explained by hemodynamics, laminar flow 
patterns, vascular diameter, and aortic arch morphology, 
all of which play a role in cardioembolic stroke’s lateral-
ity.25,26 Elsaid et al26 studied the relationship between car-
dioembolic stroke and aortic arch morphology and found 
that cardioembolic strokes tend to occur more frequently 
in the anterior circulation, left MCA territory. Another 
possible explanation is that patients with an underlying 
stenosis, especially if severe, may have had definitive 
revascularization (angioplasty or stenting) during the iMT 
or shortly thereafter or even early carotid endarterec-
tomy, creating a bias in our dataset.
Mosimann et al27 showed in their study of predictors 
of early reocclusion after MT that the majority of early 
reocclusions occurred in patients with residual embolic 
fragments that were not recognized on the final control 
run, misinterpreted as focal spasm, or were suboptimally 
imaged due to overlapping branches.
Other possibility for rLVO in the same location is local 
vascular endothelial injury caused by the iMT maneu-
ver itself. Previous studies have shown that endothelial 
injury from the MT can result in a predilection to acute in-
situ thrombosis and reocclusion.28 In preclinical studies, 
thrombectomy-induced vascular wall damage was found 
to manifest as endothelial injury, disruption of the internal 
elastic lamina, and focal edema located in the intimal and 
medial layers of the vessel.29 Additionally, more than half 
of clots retrieved from patients treated with MT contained 
endothelial cells, suggesting intimal layer damage due to 
direct mechanical injury from MT.29 Anecdotaly, one of 
our patients with cardioembolic stroke with atrial fibril-
lation developed fixed focal stenosis after the third rMT 
in the same vascular territory that required angioplasty.
The optimal timing for initiation of antithrombotic 
therapy in patients presenting with acute cardioembolic 
LVO is controversial. In the current guidelines, no avail-
able prospective data address the appropriate timing for 
initiation of anticoagulation or antiplatelet agent after MT, 
especially when intravenous thrombolysis is given. The 
dilemma is that there is an increased risk of early recur-
rent stroke for patients with atrial fibrillation, intracar-
diac thrombi, unstable plaques, or extensive intracranial 
stenosis. However, there is also a known increased risk 
of hemorrhagic transformation of the infarcted tissue.30 
A protocol has been proposed to address the timing of 
anticoagulation timeline in patients with a cardioembolic 
source based on the index stroke volume.31 Retrospec-
tive studies of early reocclusion after successful MT 
have found a relationship between atherosclerotic dis-
ease, preprocedural platelet counts, and the rate of rLVO, 
concluding that pretreatment antiplatelet therapy might 
reduce the rate of recurrence.32 In our cohort, 24% of 
patients with rLVO were not on antiplatelet or anticoagu-
lant therapy before the reocclusion. Patients with early 
rLVO during hospitalization were less frequently started 
on antithrombotic therapy after iMER than the late rLVO 
group (34% versus 5%, P=0.022). These data suggest 
that earlier initiation of antithrombotic therapy may pre-
vent rLVO, but this needs to be balanced against the 
risk of intracerebral hemorrhage related to early initia-
tion of antithrombotic therapy. More prospective data are 
needed to study the role of early versus late initiation of 
antithrombotic therapy after MT.
First pass revascularization was achieved in 32 of the 
54 rLVO patients during iMT (59%) and in 26 of the 54 
during rMT (48%). All 54 patients with rLVO had initial 
successful reperfusion on iMT (modified Thrombolysis 
in Cerebral Infarction 2b/3), and rMT led to successful 
recanalization in 51 patients (94%), mostly with the com-
bination of stent retrieval and aspiration. Postprocedural 
neurological deficits were worse after the rMT compared 
with iMT (median NIHSS 12 versus 7, P=0.008). This 
finding is expected since the patients undergoing rMT 
already had deficit from the index stroke. Reassuringly, 
the rate of intracerebral hemorrhage was not substan-
tially different with rMT compared with the iMT and 
accepted rates seen in trials of MT.33
Data on the safety and long-term outcomes of MT in 
the setting of high premorbid mRS are limited. The AHA/
ASA guidelines state that patients with premorbid mRS 
score >1 have uncertain benefits and further randomized 
controlled trials are necessary.34 Seker et al35 showed 
that patients with premorbid mRS score 3 to 4 could 
return to their premorbid mRS after MT, which can justify 
MT for those patients. These considerations are relevant 
to the consideration of performing rMT in patients with 
rLVO. Thirty-five of the 54 patients had rMT during the 
index hospitalization due to early reocclusion. Although 
not strictly within the guidelines, treatment with rMT for 
these patients may have been reasonable because of the 
short period since the initial stroke, being already hos-
pitalized and could potentially be treated ultra-early. At 
discharge time, 30% had minimal or no disability (mRS 
score ≤2) after rMT, 50% had moderate to severe dis-
ability (mRS score 3–5). Based on this study’s results, 
these patients’ outcomes seem to be acceptable with 
a favorable discharge mRS of 30%, which would be 
expected to rise at 3 months. Furthermore, patients with 
rLVO may be sicker and may have a worse functional 
baseline from their previous stroke, which may negatively 
affect functional recovery after rMT.
Again, we have no doubt that judicious patient selec-
tion played a role in selecting patients with rLVO for 
rMT, contributing to some of the good outcomes that 
we observed.
Overall mortality in our cohort was 20%, comparable 
to other recurrent large vessel occlusion studies (18%–
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mortality figures (10%–15%) reported in the randomized 
thrombectomy trials.36
Our study has limitations, mainly its retrospective 
nature. Also, the low rate of rLVO requiring rMT ham-
pered our ability to do multivariable regression analysis. 
We have missing outcomes data for 4 patients treated 
with MT. However, our cohort’s rate of favorable func-
tional outcomes is comparable to other rMT studies and 
is only slightly less than the landmark randomized trials. 
Our data clearly underestimate the absolute rate of rLVO 
since we only captured patients who qualified for rMT. 
Since we only had outcome data at hospital discharge, 
our data may underestimate the good neurological out-
come rate with rMT, which is better assessed at 90 to 
180 days. Finally, the study centers are comprehensive 
stroke centers in the United States; practices and patient 
selection for rMT may be different in other health care 
systems worldwide.
CONCLUSIONS
To our knowledge, this is the largest multicenter study 
in North America of rLVO requiring rMT. Almost 2% 
of patients treated with MT experience rLVO, usually 
of a previously treated artery during the same hospi-
talization. Repeat MT seems to be safe and effective 
for attaining vessel recanalization, and good outcome 
can be expected in 30% of patients. Inadequate anti-
coagulation or antiplatelet therapy and a cardioem-
bolic source may be risk factors for early rLVO. Further 
research is needed to better understand the true rate 
or rLVO after MT, and to identify optimal treatment 
strategies to minimize this risk.
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